News
-
-
PRESS RELEASE
ARTCLINE secures additional €3.4 million in funds to support commercialization of its ARTICE® immune cell therapy for treatment of septic shock
ARTCLINE secures €3.4 million to support commercialization of ARTICE® immune cell therapy for septic shock. New financing from investors like MBG MV -
-
PRESS RELEASE
ARTCLINE achieves milestone in septic shock: Patient recruitment for the ReActIF-ICE study successfully completed
ARTCLINE completes patient recruitment for ReActIF-ICE study in septic shock, evaluating ARTICE® immune cell therapy. Study results to be presented at DIVI Congress Dec. 2026 -
-
PRESS RELEASE
ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy
ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board, accelerating commercialization of innovative sepsis therapy with ARTICE® therapy for immune dysfunction in septic shock -
-
-
-
PRESS RELEASE
ARTCLINE: rapid progress in multicenter clinical study on immune support in septic shock – 100 patients enrolled
ARTCLINE reports rapid progress in multicenter clinical study on immune support in septic shock with 100 patients already enrolled. Study aims to validate ARTICE(R) therapy benefits for critical condition treatment
